Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis

Conus, Sébastien; Straumann, Alex; Simon, Hans-Uwe (2009). Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis. Journal of allergy and clinical immunology, 123(1), 269; author reply 269-70. St. Louis, Mo.: Mosby 10.1016/j.jaci.2008.09.031

Full text not available from this repository. (Request a copy)

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology

UniBE Contributor:

Simon, Hans-Uwe

ISSN:

0091-6749

Publisher:

Mosby

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:10

Last Modified:

04 May 2014 23:22

Publisher DOI:

10.1016/j.jaci.2008.09.031

PubMed ID:

18951621

Web of Science ID:

000262793900049

URI:

https://boris.unibe.ch/id/eprint/30720 (FactScience: 194998)

Actions (login required)

Edit item Edit item
Provide Feedback